CIK 0001590877
- Non-accelerated filer
- Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 471851754
- Phone
- +1 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- Open-market buys, last 90 days
- $949,381
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$949,381. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-07-18 | Christmas Patrick J. SVP, General Counsel | Exercise or conversion · Stock Option (Right to Buy) | −100 | 9,541 | ||
| 2019-06-30 | Christmas Patrick J. SVP, General Counsel | Grant or award | +52 | $36.83 | $2K | 3,058 |
| 2019-06-19 | Mills Kenneth T. President and CEO | Exercise or conversion | +15,000 | $0.85 | $13K | 261,000 |
| 2019-06-19 | Mills Kenneth T. President and CEO | Sale | −10,880 | $52.27 | $569K | 250,120 |
| 2019-06-19 | Mills Kenneth T. President and CEO | Sale | −4,120 | $53.25 | $219K | 246,000 |
| 2019-06-19 | Mills Kenneth T. President and CEO | Exercise or conversion · Employee Stock Option (Right to Buy) | −15,000 | 114,670 | ||
| 2019-06-18 | Christmas Patrick J. SVP, General Counsel | Exercise or conversion | +5,000 | $12.10 | $61K | 8,006 |
| 2019-06-18 | Christmas Patrick J. SVP, General Counsel | Sale | −2,966 | $52.74 | $156K | 5,040 |
| 2019-06-18 | Christmas Patrick J. SVP, General Counsel | Sale | −1,934 | $53.29 | $103K | 3,106 |
| 2019-06-18 | Christmas Patrick J. SVP, General Counsel | Sale | −100 | $54.75 | $5K | 3,006 |
| 2019-06-18 | Christmas Patrick J. SVP, General Counsel | Exercise or conversion · Employee Stock Option (Right to Buy) | −5,000 | 44,931 | ||
| 2019-05-31 | Fox Allan M. Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2019-05-31 | Tasse Daniel Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2019-05-31 | STUMP DAVID C Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2019-05-31 | KARABELAS ARGERIS N Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2019-05-31 | HAYDEN DONALD J JR Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2019-05-31 | Glucksmann Alexandra Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2019-05-31 | BESHAR LUKE M Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2019-05-31 | Abdun-Nabi Daniel Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2019-05-28 | Simpson Curran SVP, Product Development & CTO | Exercise or conversion | +18,000 | $22.00 | $396K | 57,500 |
Page 27 of 43 · 852 trades